HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Mahadevan, M. S. Articles by Benson, P. V. Search for Related Content PubMed PubMed Citation Articles by Mahadevan, M. S. Articles by Benson, P. V. Related Collections Molecular Diagnostics and Genetics

Factor V Null Mutation Affecting the Roche LightCycler Factor V Leiden Assay

¹ Department of Pathology, University of Virginia, Charlottesville, VA;
² Ohio State University, Columbus, OH;

^aaddress correspondence to this author at: Department of Pathology, University of Virginia, MR5 Building, Rm. 3330, 415 Lane Rd., PO Box 800904, Charlottesville, VA 22908-0904; fax 434-924-1545, e-mail mahadevan@virginia.edu

The first 20% of the full text of this article appears below.

Although the role of factor V as a coagulation factor is more familiar, it has an equally important alternative role as a cofactor for protein C. Activated protein C (APC) is important in a naturally occurring anticoagulant pathway in which it cleaves factor V, thereby controlling the concentrations of factor V. The factor V Leiden mutation (1), which has a frequency of 1% in Caucasian populations and accounts for most cases of (APC) resistance, makes factor V resistant to cleavage by APC. Heterozygosity for the factor V Leiden mutation confers an increased lifelong relative risk for venous thrombosis, whereas homozygosity for the factor V Leiden mutation confers an even greater increased lifelong risk. Because of its high prevalence and association with thrombophilic disorders, a variety of assays have been developed to detect the GA mutation at nucleotide 1691, codon 506, of the factor V gene, including assays based on use of the LightCycler^TM (2)(3). In this report we present a case of an anomalous result obtained with the Roche LightCycler assay for factor V Leiden and discuss its implications.

Recently, a 52-year-old female was diagnosed with deep venous thrombosis at our institution. As part of her assessment, she underwent a routine work-up for hypercoagulation. Her partial thromboplastin time and prothrombin time were normal before she was treated with anticoagulants. Measurements of protein C, protein S, and anti-thrombin III were deferred until she was finished with coumadin. Meanwhile, results from molecular diagnostics testing included a negative result for the GA mutation at nucleotide 20210 in the prothrombin gene. However, an assay for the factor V Leiden mutation performed on the . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				R. P. Agarwal, S. M. Peters, M. Shemirani, and N. von Ahsen Improved Real-Time Multiplex Polymerase Chain Reaction Detection of Methylenetetrahydrofolate Reductase (MTHFR) 677C>T and 1298A>C Polymorphisms Using Nearest Neighbor Model-Based Probe Design J. Mol. Diagn., July 1, 2007; 9(3): 345 - 350. [Abstract] [Full Text] [PDF]

				E. Lyon Discovering Rare Variants by Use of Melting Temperature Shifts Seen in Melting Curve Analysis Clin. Chem., August 1, 2005; 51(8): 1331 - 1332. [Full Text] [PDF]